An interventional study of Blood samples will be taken for pharmacokinetics and pharmacogenetics in Resistant Arterial Hypertension, sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.
Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Hypertension with a site in Russian Federation — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · Russian Federation.
Among the 88 studies in Hypertension with a site in Russian Federation, this one is the 36th largest by planned enrollment of the 60 interventional ones that give a count, is the only one that started in 2022, is one of 8 with no phase, and was the 82nd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →6 of the 88 studies in Hypertension with a site in Russian Federation are open now. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russian Federation
Ages 45–60 · Women only
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russian Federation
Ages 18+ · Healthy volunteers
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 65+
Gedeon Richter Plc. · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 30 · Phase 4 10
First in 2000; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 348 across the 60 interventional studies, 1,224 across the 28 observational. Of the 73 that completed or were terminated, 33 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 88 have an industry lead sponsor. The 10 most frequent:
Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Ryazan State Medical University has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 88 studies in Hypertension with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was planned to assess the concentration of antihypertensive drugs in the blood plasma in patients with controlled and uncontrolled arterial hypertension. Methods: it is planned to include patients with arterial hypertension taking 3 antihypertensive drugs (indapanide, lisinopril or valsartan, amlodipine). Based on the results of 24-hour blood pressure monitoring, the patients will be randomized into two groups: The first group - the patients with controlled AH; The second group - the patients with uncontrolled AH. Venous blood was taken in both groups of the patients in the morning before and 2 hours after taking drugs to assess the concentration of lisinopril, amlodipine, valsartan and indapamide. Concentation of assesed antihypertensive drugs will be compared in both groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Controlled arterial hypertension according the results of 24-hour blood pressure monitoring. Blood samples will be taken for pharmacokinetics and pharmacogenetics
Diagnostic Test: Blood samples will be taken for pharmacokinetics and pharmacogenetics
Uncontrolled arterial hypertension according the results of 24-hour blood pressure monitoring. Blood samples will be taken for pharmacokinetics and pharmacogenetics
Diagnostic Test: Blood samples will be taken for pharmacokinetics and pharmacogenetics
To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
Plasma Concentration of lisinopril, valsartan, amlodipin, indapamide, metoprolol
Number of Participants with antihypertensive drug concentraion below the limit of quantitative determination
Time frame: day 1
Started Mar 2022 (actual). Primary completion is estimated for Nov 2024, 32 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 32 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ryazan State Medical University